Evenity (Romosozumab) and Your Kidneys: Renal Protection, Renal Risk, and What Women Need to Know

What Is Romosozumab and Why Does the Kidney Question Matter?

Romosozumab (Evenity) is a monoclonal antibody that targets sclerostin, a protein produced by osteocytes that normally puts the brakes on bone formation. By blocking sclerostin, romosozumab does something most bone drugs cannot: it simultaneously stimulates bone formation and reduces bone resorption, a dual effect called "uncoupling" the remodeling cycle. The FDA approved romosozumab in April 2019 specifically for postmenopausal women with osteoporosis at high or very high fracture risk.

The kidney question arises for two reasons. First, many postmenopausal women with osteoporosis also have age-related decline in kidney function. Second, other bone drugs, particularly bisphosphonates and denosumab, carry real renal restrictions, so women and their clinicians reasonably ask whether romosozumab carries similar baggage.

Short answer: it does not cause kidney damage the way bisphosphonates can, and it is not renally cleared. The more nuanced answer involves hypocalcemia risk in kidney disease, an indirect pathway that can become genuinely dangerous if overlooked.

How Romosozumab Is Cleared From the Body

Romosozumab is an IgG2 monoclonal antibody. Like other therapeutic monoclonal antibodies, it is primarily eliminated through receptor-mediated endocytosis and intracellular proteolysis, not through glomerular filtration or tubular secretion. This means that a woman with an eGFR of 25 mL/min/1.73m² clears the drug through roughly the same biological pathway as a woman with an eGFR of 90 mL/min/1.73m². The kidneys are bystanders in the pharmacokinetic story.

Population pharmacokinetic analyses from the romosozumab development program showed that creatinine clearance had no clinically meaningful effect on romosozumab exposure, and no dose adjustment is required based on renal function alone.

Where the Renal Concern Is Real: Hypocalcemia

Romosozumab shifts the balance sharply toward bone formation. Rapid mineralization of new bone matrix requires large amounts of calcium, which the drug pulls from the extracellular fluid. In women with intact kidneys and adequate dietary calcium and vitamin D, the parathyroid hormone response compensates quickly. In women with CKD stages 3b through 5, compensatory mechanisms are impaired for three overlapping reasons.

First, the kidney cannot efficiently activate vitamin D to calcitriol, reducing intestinal calcium absorption. Second, secondary hyperparathyroidism already stresses calcium homeostasis before the drug is even started. Third, dialysis patients have essentially no renal calcium conservation, leaving them dependent on dietary intake and supplementation alone.

The result: severe hypocalcemia, which can trigger QT prolongation, tetany, and cardiac arrhythmia. The romosozumab prescribing information explicitly states that hypocalcemia must be corrected before initiating treatment, and ongoing calcium and vitamin D supplementation is mandatory throughout the 12-month course.

The ARCH Trial: What It Actually Shows About Renal Outcomes

The ARCH trial (Saag et al., NEJM 2017) compared 12 months of romosozumab 210 mg subcutaneously monthly followed by alendronate, versus alendronate alone for a total of 24 months, in 4,093 postmenopausal women with osteoporosis and a prior vertebral fracture. The primary result was a 48% reduction in new vertebral fractures in the romosozumab-then-alendronate group versus alendronate alone at 24 months. Hip fracture risk fell by 38%.

ARCH was not designed to measure kidney outcomes. Renal function was not a pre-specified secondary endpoint. Patients with an eGFR below approximately 30 mL/min/1.73m² were generally excluded. This is a meaningful evidence gap: the women most likely to have concurrent CKD and osteoporosis, those in their 60s and 70s with hypertension or diabetes-related nephropathy, are precisely the population least represented in the trial data.

A practical framework for thinking about romosozumab across CKD stages follows:

| CKD Stage | eGFR (mL/min/1.73m²) | Romosozumab Feasibility | Key Monitoring Priority | |---|---|---|---| | G1 (Normal) | ≥90 | Standard use | Baseline calcium/25-OH-D | | G2 (Mild) | 60-89 | Standard use | Repeat calcium at month 1 | | G3a/b (Moderate) | 30-59 | Usable with vigilance | Monthly calcium, PTH baseline | | G4 (Severe) | 15-29 | Limited data; individual risk-benefit | Correct secondary hyperparathyroidism first | | G5/Dialysis | <15 or dialysis | Not studied; avoid unless specialist-supervised | Avoid unless compelling indication |

Romosozumab Compared to Other Bone Drugs: Where the Kidney Risk Actually Lives

Bisphosphonates and the Kidney

Oral and intravenous bisphosphonates present real renal toxicity risk. Zoledronic acid is contraindicated when eGFR is <35 mL/min/1.73m², and alendronate is generally avoided below eGFR 30-35 mL/min/1.73m². Bisphosphonates accumulate in bone and are renally cleared, meaning impaired kidneys slow their elimination and raise exposure.

Romosozumab does not share this mechanism. Its renal profile is categorically different from bisphosphonates, and this distinction matters for the woman with CKD stage 3b who has already been told she "can't take the bone drugs."

Denosumab and the Rebound Risk

Denosumab (Prolia) can be used at any level of kidney function without dose adjustment, but it carries a different problem: rebound vertebral fractures when discontinued. Denosumab also causes severe hypocalcemia in CKD patients, requiring the same meticulous electrolyte correction that romosozumab does. The FDA label for denosumab specifically flags hypocalcemia risk in patients with severe renal impairment.

The sequencing question of romosozumab followed by denosumab, or the reverse, is clinically active because denosumab cannot simply be stopped at the end of its course without transitioning to a bisphosphonate. Women who cycle through these agents need a long-term sequencing plan, not just a 12-month prescription.

Teriparatide and Abaloparatide

PTH-receptor agonists have no meaningful renal dosing restriction. They serve a similar anabolic niche to romosozumab, though the fracture reduction magnitude is generally smaller in direct comparisons.

Life Stage and Bone Loss: Who Gets to Romosozumab and When

Postmenopausal Women (the Primary Population)

Estrogen loss at menopause accelerates bone resorption by increasing osteoclast activity. The first 5 to 10 years after the final menstrual period represent the steepest phase of bone loss. Women who enter perimenopause with lower bone density, those who smoked, had low calcium intake, or used long-term glucocorticoids, may reach osteoporosis fracture thresholds in their late 50s rather than their late 60s.

The Menopause Society (NAMS) 2021 position statement on osteoporosis notes that menopausal hormone therapy reduces bone turnover and preserves density, but is not considered primary pharmacotherapy for established osteoporosis. Women at very high fracture risk, defined as a prior fragility fracture or a T-score below minus 2.5 with additional clinical risk factors, are candidates for anabolic agents like romosozumab before transitioning to antiresorptive therapy.

Romosozumab is approved only for postmenopausal women. The trials enrolled women aged 55 to 90 years. The mean age in ARCH was 74 years.

Perimenopause: The Gray Zone

A perimenopausal woman with rapidly declining bone density, a condition sometimes called "early bone loss," is not an approved candidate for romosozumab. The drug has not been studied in premenopausal or perimenopausal women, and the hormonal fluctuation of perimenopause complicates the sclerostin-pathway biology. Women in this life stage who are losing bone quickly are better served by stabilizing estrogen levels (if appropriate) and addressing modifiable risk factors while awaiting definitive postmenopausal assessment.

Reproductive Years and PCOS

Women with polycystic ovary syndrome have complex bone metabolism. Androgen excess and insulin resistance can exert modest bone-protective effects, but chronic amenorrhea in lean women with PCOS increases fracture risk. PCOS-associated bone physiology in younger women remains understudied. Romosozumab is not indicated in this population and would be contraindicated if the woman could become pregnant.

Pregnancy, Lactation, and Contraception: A Required and Serious Section

Romosozumab is contraindicated in pregnancy. This is not a soft caution. It is a hard stop.

Animal studies showed fetal harm at doses below the human therapeutic exposure. In rodent and primate reproductive studies, romosozumab caused fetal skeletal abnormalities and embryotoxicity. Human data are absent for obvious ethical reasons, but the mechanism, sclerostin inhibition during fetal bone development, gives no reason for reassurance. Sclerostin plays a biologically active role in skeletal morphogenesis.

For women of reproductive potential, the prescribing information states that pregnancy should be excluded before starting romosozumab, and effective contraception must be used throughout the 12-month treatment course and for at least 3 months after the final injection. The half-life of romosozumab is approximately 6.4 days, meaning the drug is largely cleared within about 5 to 6 weeks after the last dose, but the 3-month post-treatment contraception window accounts for the outer tail of pharmacokinetic variability.

Lactation: There are no human lactation studies. IgG antibodies transfer into breast milk to varying degrees. Given the absence of data and the theoretical risk of altering an infant's sclerostin-mediated bone development, the prescribing label recommends against use during breastfeeding. If romosozumab is medically necessary for the mother, breastfeeding should be discontinued.

Practical note: Because romosozumab is labeled only for postmenopausal women, pregnancy and breastfeeding exposure would represent off-label use. Any woman younger than 50 who is being considered for romosozumab on compassionate or off-label grounds must have a documented discussion of these risks and confirmed non-pregnant status before each monthly injection.

The Cardiovascular Black Box: A Women's-Health Lens

The cardiovascular warning on romosozumab is the most prominent safety signal on the label, and it deserves specific attention for women because cardiovascular disease is the leading cause of death in women over 65, the same population at highest osteoporosis risk.

ARCH showed a numerical excess of serious cardiovascular events in the romosozumab group compared with alendronate during the 12-month treatment phase: 2.5% versus 1.9%. The FRAME trial (Cosman et al., NEJM 2016), which compared romosozumab to placebo in 7,180 women, did not show the same imbalance. The discrepancy is partly attributed to the cardioprotective effects of alendronate in the comparator arm rather than a pure romosozumab hazard, but regulators opted for a black box because the signal was present and the population is high risk.

Current FDA labeling states: do not initiate romosozumab in patients who have had a myocardial infarction or stroke within the preceding 12 months. For women with a recent acute coronary syndrome, the guideline-recommended approach is to defer romosozumab and consider teriparatide or abaloparatide instead.

Women with controlled hypertension, stable coronary artery disease, or a history of cardiovascular risk factors who are more than 12 months from an acute event are not automatically excluded. The benefit-risk calculation in a woman with a T-score of minus 3.5 and a prior hip fracture often favors treatment.

Practical Monitoring Protocol for Women on Romosozumab

Before the First Injection

• Serum calcium, albumin-corrected or ionized
• 25-hydroxyvitamin D (correct to ≥30 ng/mL before starting)
• Serum creatinine and eGFR
• PTH if eGFR <45 mL/min/1.73m² or clinical suspicion of secondary hyperparathyroidism
• Exclude pregnancy if reproductive potential
• Cardiovascular history review; confirm no MI/stroke in prior 12 months
• Dental evaluation if feasible (osteonecrosis of the jaw risk is low but non-zero with anabolic agents; more relevant if transitioning to bisphosphonate afterward)

During the 12-Month Course

• Calcium and vitamin D supplementation throughout: standard recommendation is calcium 1,000 to 1,200 mg/day total dietary plus supplement, vitamin D 800 to 1,000 IU/day
• Recheck serum calcium at month 1, particularly in women with CKD or low dietary calcium
• Symptom check at each visit: perioral tingling, muscle cramps, or palpitations suggest hypocalcemia and warrant urgent calcium measurement

After the Final Injection

• Transition to antiresorptive therapy promptly. Without a follow-on agent, the bone gained during romosozumab treatment is lost within 12 to 24 months. The ARCH trial transition to alendronate is the best-studied sequence and is now standard of care.
• Bone density assessment (DXA) 12 to 24 months after starting the antiresorptive agent
• In women who cannot use bisphosphonates after romosozumab, denosumab is the alternative, though discontinuation of denosumab requires its own careful exit strategy

Evidence Gaps Specific to Women: What We Do Not Know

Women have been included in the major romosozumab trials, but specific subgroups remain poorly characterized.

Women with CKD stages 4 and 5 were excluded from ARCH and FRAME. Post-marketing case reports and small case series suggest severe hypocalcemia is the dominant risk in this group, not kidney injury from the drug itself. Whether romosozumab provides meaningful fracture reduction in CKD-related bone disease (renal osteodystrophy) is genuinely unknown.

Premenopausal women with secondary osteoporosis (from glucocorticoid use, anorexia nervosa, or aromatase inhibitor therapy for breast cancer) represent a real unmet need. Aromatase inhibitor-induced bone loss is significant: women on aromatase inhibitors lose bone at rates comparable to surgical menopause. Romosozumab has not been studied in this population in a randomized trial.

Ethnic and racial diversity in the trials was limited. Bone geometry and fracture patterns differ across ancestral groups, and sclerostin levels vary with race. Whether the 48% vertebral fracture reduction generalizes uniformly across Black, Asian, and Hispanic women is extrapolated rather than directly established.

Women with autoimmune kidney disease such as lupus nephritis, who may be both young and facing both renal impairment and glucocorticoid-induced bone loss, have no trial data at all.

The Women's Bone Health Network, a collaborative research group, has called for dedicated trials in women with CKD stages 3b to 4 using romosozumab. No such trial is currently listed in active recruitment on ClinicalTrials.gov as of this writing.

Who Is and Is Not Right for Romosozumab: A Life-Stage Summary

Good candidates:

• Postmenopausal women with a prior vertebral or hip fragility fracture and T-score <minus 2.5
• Women at very high fracture risk who have failed or are intolerant of bisphosphonates
• Women who need rapid bone density gains (romosozumab produces more density accrual in 12 months than bisphosphonates do in 3 years)
• Women with CKD stages 1 to 3a who have corrected calcium and vitamin D and no secondary hyperparathyroidism

Poor candidates or situations requiring specialist input:

• Women who had a heart attack or stroke within the past 12 months
• Women with CKD stages 4 to 5 or on dialysis (insufficient safety data; hypocalcemia risk is high)
• Women who are pregnant, trying to conceive, or breastfeeding
• Perimenopausal or premenopausal women (off-label, no trial data)
• Women with uncorrected hypocalcemia
• Women with a history of osteonecrosis of the jaw or atypical femur fracture from prior antiresorptive therapy (the fracture mechanism differs, but bone quality history matters)